RAS and leukemia: From basic mechanisms to gene-directed therapy

Journal of Clinical Oncology

Volumn 17, Issue 3, 1999, Pages 1071-1079

  Beaupre, Darrin M ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ALCOHOL DERIVATIVE; LIMONENE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; PEPTIDE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TERPENE;

DRUG MECHANISM; DRUG SPECIFICITY; GENE ACTIVATION; GENE FUNCTION; GENE MUTATION; HUMAN; LEUKEMIA; MULTIGENE FAMILY; NONHUMAN; ONCOGENE RAS; PRENYLATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033014304     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.3.1071     Document Type: Review

References (116)

1. Quinn MT: Low-molecular-weight GTP-binding proteins and leukocyte signal transduction. J Leukoc Biol 58:263-276, 1995
2. Bokoch GM, Der CJ: Emerging concepts in the Ras superfamily of GTP-binding proteins. FASEB J 7:750-759, 1993
3. Boguski MS, McCormick F: Proteins regulating Ras and its relatives. Nature 366:643-653, 1993
4. Melchior F, Gerace L: Two-way trafficking with Ran. Trends Cell Biol 8:175-179, 1998
5. Jhanwar SC, Neel BG, Hayward WS, et al: Localization of c-ras oncogene family on human germ-line chromosomes. Proc Natl Acad Sci U S A 80:4794-4797, 1983
6. Carlson M, Nakamura Y, O'Connell P, et al: Isolation and mapping of a polymorphic DNA sequence for N-RAS pMCR3 on chromosome 1. Nucleic Acids Res 15:9623-626, 1987
7. Lowy DR, Willumsen BM: Function and regulation of ras. Annu Rev Biochem 62:851-891, 1993
8. Cox AD, Der CJ: The ras/cholesterol connection: Implications for Ras oncogenicity. Crit Rev Oncog 3:365-400, 1992
9. Ellis RW, Defeo D, Shih TY, et al: The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature 292:506-511, 1981
10. Ruta M, Wolford R, Dhar R, et al: Nucleotide sequence of the two rat cellular H-ras genes. Mol Cell Biol 6:1706-1710, 1986
11. Shimizu K, Goldfarb M, Suard Y, et al: Three human transforming genes are related to the viral oncogenes. Proc Natl Acad Sci U S A 80:2112-2116, 1983
12. Rodenhuis S: Ras and human tumors. Semin Cancer Biol 3:241-247, 1992
13. Almoguera C, Shibata D, Forrester K, et al: Most human carcinomas of the exocrine pancreas contain mutant K-ras genes. Cell 53:549-554, 1988
14. Hruban RH, van Mansfeld AD. Offerhaus GJ, et al: K-ras oncogene activation in adenocarcinoma of the human pancreas: A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis allele-specific oligonucleotide hybridization. Am J Pathol 143:545-554, 1993
15. Wang ZY, Liu TH, Cui QC: Gene diagnosis of pancreatic adenocarcinoma. Chin J Pathol 23:270-273, 1994
16. Enomoto T, Inoue M, Perantoni AO, et al: K-ras activation in neoplasms of the human female reproductive tract. Cancer Res 50:6139-6145, 1990
17. Wong YF, Chung TK, Cheung TH, et al: Frequent ras gene mutations in squamous cell cervical cancer. Cancer Lett 95:29-32, 1995
18. Lemoine NR, Mayall ES, Wyllie FS, et al: Activated ras oncogenes in human thyroid cancers. Cancer Res 48:4459-4463, 1988
19. Oyama T, Suzuki T, Hara F, et al: N-ras mutation of thyroid tumor with special reference to the follicular type. Pathol Int 45:45-50, 1995
20. Suarez HG, du Villard JA, Severino M, et al: Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5:565-570, 1990
21. Levi S, Urbano-Ispizua A. Gill R, et al: Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 51:3497-3502, 1991
22. Tada M, Yokosuka O, Omata M, et al: Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing. Cancer 66:930-935, 1990
23. Tada M, Omata M, Ohto M: High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Cancer 69:1115-1118, 1992
24. Breevik J, Meling GI, Spurkland A, et al: K-ras mutation in colorectal cancer: Relations to patient age, sex, and tumor location. Br J Cancer 69:367-371, 1994
25. Wang ZY: Detection of Ki-ras oncogene mutations in normal mucosa, adenoma and adenocarcinoma of the colon. Chin J Pathol 22:333-336, 1993
26. Forrester K, Almoguera C, Han K, et al: Detection of high incidence of K-ras oncogenes during human carcinogenesis. Nature 327:298-303, 1987
27. Bos JL, Fearon SR, Hamilton SR, et al: Prevalence of ras mutations in human colorectal cancers. Nature 327:293-297, 1987
28. Pierceall WE, Goldberg LH, Tainsky MA, et al: Ras gene mutations and amplification in human nonmelanoma skin cancers. Mol Carcinog 4:196-202, 1991
29. Rodenhuis S, Slebos RJC: Ras oncogenes and human lung cancer. Am Rev Respir Dis 142:S27-30, 1990
30. Li S, Rosell R, Urban A, et al: K-ras gene point mutation: A stable tumor marker in non-small-cell lung carcinoma. Lung Cancer 11:19-27, 1994
31. Mills NE, Fishman CL, Rom WN, et al: Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 55:1444-1447, 1995
32. Fujimoto I, Shimizu Y, Hirai Y, et al: Studies on ras oncogene activation in endometrial carcinoma. Gynecol Oncol 48:196-202, 1993
33. Sasaki H, Nishii H, Takahashi H, et al: Mutation of the Ki-ras proto-oncogene in human endometrial hyperplasia and carcinoma. Cancer Res 53:1906-1910, 1993
34. Carr J, Mackie RM: Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol 131:72-77, 1994
35. Van't Veer LJ, Burgering BMT, Versteeg R, et al: N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 9:3114-3116, 1989
36. Albino AP, Nanus DM, Mentle IR, et al: Analysis of ras oncogenes in malignant melanoma and precursor lesions: Correlation of point mutations with different phenotype. Oncogene 4:1363-1374, 1989
37. Herlyn M, Satyamoorthy K: Activated ras, yet another player in melanoma. Am J Pathol 149:739-744, 1996
38. Hirsch-Ginsberg C, Lemaistre AC, Kantarjian H, et al: Ras mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia but are prevalent in chronic myelomonocytic leukemia. Blood 76:1214-1219, 1990
39. Nounou R, Estey E. Beran M, et al: Mutation of K-, N-, and H-RAS oncogenes in patients with myelodysplastic syndrome (MDS). Blood 88:208b (abstr 3559) (suppl 1)
40. Imamura N, Kuramoto A. Ishihara H, et al: Detection of high incidence of H-RAS oncogene point mutations in acute myelogenous leukemia. Am J Hematol 43:151-153, 1993
41. Ahuja HG, Foti A. Bareli M, et al: The pattern of mutational involvement of ras genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 75:1684-1690, 1990
42. Janssen JWG, Steenvoorden ACM, Lyons J, et al: Ras gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci USA 84:9228-9232, 1987
43. Kalra R, Paderanga DC, Olson K, et al: Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. Blood 84:3435-3439, 1994
44. Miyauchi J, Asada M, Sasaki M, et al: Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood 83:2248-2254, 1994
45. Lubbert M, Mirro J, Miller CW, et al: N-Ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood 75:1163-1169, 1990
46. Neri A, Knowles DM, Greco A, et al: Analysis of ras oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci U S A 85:9268-9272, 1988
47. Corradini P. Ladetto M, Voena C, et al: Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood 81:2708-2713, 1993
48. Paquette RL, Berenson J, Lichtenstein A, et al: Oncogenes in multiple myeloma-point mutations of N-ras. Oncogene 5:1659-1663, 1990
49. Liu P, Leong T, Quam L, et al: Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 88:2699-2706, 1996
50. Trumper L, Pfreundschuh M, Jacobs G, et al: N-ras genes are not mutated in Hodgkin and Reed Sternberg cells: Results from single-cell polymerase chain reaction examinations. Leukemia 10:727-730, 1996
51. Clark HM, Yano T, Sander C, et al: Mutation of the ras genes is a rare genetic event in the histologic transformation of follicular lymphoma. Leukemia 10:844-847, 1996
52. Hamatani K, Nagata Y, Abe M, et al: Increased expression of ras genes in non-Hodgkin's lymphomas is not associated with oncogenic activation of those genes by point mutation. Jpn J Cancer Res 80:706-710, 1989
53. Sawyers CL, McLaughlin J, Witte ON: Genetic requirement for ras in the transformation of fibroblasts and hematopoietic cells by the bcr-abl oncogene. J Exp Med 181:307-313, 1995
54. Pendergast AM, Quilliam LA, Cripe LD, et al: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175-185, 1993
55. Bollag G, Clapp DW, Shih S, et al: Loss of NFl results in activation of the ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144-148, 1996
56. Prendergast GC, Gibbs JB: Ras regulatory interactions: Novel targets for anti-cancer intervention. Bioessays 16:187-191, 1993
57. Maruta H, Burgess W: Regulation of the ras signaling network. Bioessays 16:489-496, 1994
58. Bollagand G, McCormick F: Regulators and effectors of Ras proteins. Annu Rev Cell Biol 1991:7:601-633
59. Denhardt DT: Signal transducing protein phosphorylation cascades mediated by Ras/Rho protein in the mammalian cell: The potential for multiplex signaling. Biochem J 318:729-747, 1996
60. Prendergast GC, Gibbs JB: Pathways of ras function: Connections to the actin cytoskeleton. Adv Cancer Res 62:19-63, 1993
61. Matsuda S, Gotoh Y, Nishida E: Signaling pathways mediated by the mitogen-activated protein (MAP) kinase kinase/MAP kinase cascade. J Leukoc Biol 56:548-553, 1994
62. Demetri GD, Ernst TJ, Pratt ES, et al: Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J Clin Invest 86:1261-1269, 1990
63. Reimann T, Buscher D, Hipskind RA, et al: Lipopolysaccharide induces activation of the raf-1/MAP kinase pathway: A putative role for raf-1 in the induction of the IL-1 beta and TNF-alpha genes. J Immunol 153:5740-5749, 1994
64. Xu GF, Lin B, Tanaka K, et al: The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63:835-841, 1990
65. Basu TN, Gutmann DH, Fletcher JA, et al: Aberrant regulation of ras proteins in malignant tumour cells from type I neurofibromatosis patients. Nature 356:713-715, 1992
66. DeClue JE, Papageorge AG, Fletcher JA, et al: Abnormal regulation of mammalian p21 ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69:265-273, 1992
67. Tamanoi F: Inhibitors of ras farnesyltransferases. Trends Biochem Sci 18:349-353, 1993
68. Willumsen BM, Norris K, Papageorge AG, et al: Harvey murine sarcoma virus p21 ras protein: Biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J 3:2581-2585, 1984
69. Jackson JH. Cochrane CG. Bourne JR, et al: Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci U S A 87:3042-3046, 1990
70. James GL, Brown MS, Cobb MH, et al: Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-RAS-transformed Rat-1 cells, but not in untransformed cells. J Biol Chem 269:27705-27714, 1994
71. Rodriguez-Viciano P, Warne PH, Khwafa A, et al: Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457-467, 1997
72. Heimbrook DC. Oliff A: Therapeutic intervention and signaling. Curr Opin Cell Biol 10:284-288, 1998
73. Kurzrock R. Gutterman JU, Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319:990-998, 1988
74. Skorski T, Kanadaraj P, Ku DH, et al: Negative regulation of p120GAP GTPase promoting activity by p210Bcr/Abl: Implication of ras-dependent Philadelphia chromosome positive cell growth. J Exp Med 179:1855-1865, 1994
75. Chuang TH, Xu X, Kaartinen B. et al: Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family. Proc Natl Acad Sci U S A 92:10282-10286, 1995
76. Sawyers CL, Denny CT: Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about. Cell 77:171-173, 1994
77. Golub TR, Barker GF, Lovett M, et al: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307-316, 1994
78. Satoh T, Endo M, Nakafuku M, et al: Platelet-derived growth factor stimulates formation of active p21 ras-GTP complex in Swiss mouse 3T3 cells. Proc Natl Acad Sci U S A 87:5993-5997, 1990
79. Gibbs JB, Marshall MS, Scolnick EM, et al: Modulation of guanine nucleotides bound to ras in NIH3T3 cells by oncogenes, growth factors, and the GTPase activating protein (GAP). J Biol Chem 265:20437-20442, 1990
80. Golub TR, Goga A, Barker GF, et al: Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 16:4107-4116, 1996
81. Prasad R, Gu Y, Alder H, et al: Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with the t(6;11) chromosome translocation. Cancer Res 53:5624-5628, 1993
82. Kuriyama M, Harada N, Kuroda S, et al: Identification of AF-6 and canoe as putative targets for ras. J Biol Chem 271:607-610, 1996
83. Largaespada DA, Brannan CI, Jenkins NA, et al: NF1 deficiency causes ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet 12:137-143, 1996
84. Shannon KM, O'Connell P, Martin GA, et al: Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 330:597-601, 1994
85. Thorn J, Molloy P. Iland H: SSCP detection of N-ras promoter mutations in AML patients. Exp Hematol 23:1098-1103, 1995
86. Tien HF, Wang CH, Chuang SM, et al: Cytogenetic studies, ras mutation, and clinical characteristics in primary myelodysplastic syndrome: A study on 68 Chinese patients in Taiwan. Cancer Genet Cytogenet 74:40-49. 1994
87. Horiike S, Misawa S, Hiroyuki N, et al: N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 8:1331-1336, 1994
88. Santon A, Arranz E, Robledo M, et al: N-ras mutations: Incidence and clinical relevance in myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol 50:315-316, 1995
89. Neubauer A, Greenberg P, Negrin R, et al: Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 8:638-641, 1994
90. Gaidano G, Guerrasio A, Serra A, et al: Molecular mechanisms of tumor progression in chronic myeloproliferative disorders. Leukemia 8:27-29, 1994
91. Casey G, Rudzki Z, Roberts M, et al: N-ras mutation in acute myeloid leukemia: Incidence, prognostic significance and use as a marker of minimal residual disease. Pathology 2:57-62, 1993
92. Coghlan DW, Morley AA, Matthews J, et al: The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia. Leukemia 8:1682-1687, 1994
93. Neubauer A, Dodge RK, George SL, et al: Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 83:1603-1611, 1994
94. De Melo MB, Lorand-Metze I, Lima CS, et al: N-ras gene point mutations in Brazilian acute myelogenous leukemia patients correlated with a poor prognosis. Leuk Lymphoma 24:309-317, 1997
95. Lee YY, Kim WS, Bang YJ, et al: Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia. Stem Cells 13:556-563, 1995
96. Gibbs JB, Oliff A. Kohl NE: Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175-178, 1994
97. Gibbs JB, Oliff A: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37:143-166, 1997
98. Crowell PL, Ren Z, Lin S, et al: Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 47:1405-1415, 1994
99. Crowell PL, Chang RR, Ren Z, et al: Selective inhibition of isoprenylation of 21-26kd proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 266:17679-17685, 1991
100. Hohl RJ, Lewis K: Differential effects of monoterpenes and lovastatin on ras processing. J Biol Chem 270:17508-17512, 1995
101. Elegbede JA, Elson CE, Tanner MA, et al: Regression of rat primary mammary tumors following dietary d-limonene. J Natl Cancer Inst 76:323-327, 1986
102. Haag JD, Lindstrom MJ. Gould MN: Limonene-induced regression of mammary carcinomas. Cancer Res 52:4021-4026, 1992
103. Stark MJ, Burke YD, McKinzie JH, et al: Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett 96:15-21, 1995
104. Moores SL, Schaber MD. Mosser SD, et al: Sequence dependence of protein isoprenylation. J Biol Chem 266:14603-14610, 1991
105. James GL, Goldstein JL, Brown MS, et al: Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells. Science 260:1937-1942, 1993
106. Kohl NE, Mosser SD, deSolms SJ, et al: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934-1937, 1993
107. Garcia M, Rowell C, Ackermann K, et al: Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J Biol Chem 268:18415-18418, 1993
108. Gelb MH, Tamanoi F, Yokoyama K, et al: The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett 91:169-175, 1995
109. Kohl NE, Omer CA, Conner MW, et al: Inhibition of farnesyl-transferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1:792-797, 1995
110. Mangues R, Corral T, Kohl NE, et al: Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res 58:1253-1259, 1998
111. Kohl NE, Wilson FR, Mosser SD, et al: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A 91:9141-9145, 1994
112. Manne V, Yan N, Carboni JM, et al: Bisubstrate inhibitors of farnesyltransferase: A novel class of specific inhibitors of ras transformed cells. Oncogene 10:1763-1779, 1995
113. Yan N. Ricca C, Fletcher J, et al: Farnesyltransferase inhibitors block the neurofibromatosis type 1 (NF1) malignant phenotype. Cancer Res 55:3569-3575, 1995
114. Bojtek AB, Der CJ: Increasing complexity of the Ras signaling pathway. J Biol Chem 273:19925-19928, 1998
115. Shannon K: The Ras signaling pathway and the molecular basis of myeloid leukemiogenesis. Curr Opin Hematol 2:305-308, 1995
116. Darley RL, Hoy TG, Baines P, et al: Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells. J Exp Med 1337-1347, 1997